Pneumococcal immunization Report uri icon
  • This report summarizes estimates of health impact and cost-effectiveness of pneumococcal immunizations that were created to assess the relative value of most of the clinical preventive services recommended by the United States Preventive Services Task Force (USPSTF) and the Advisory Committee on Immunization Practices (ACIP) for the general population. This ranking of clinical prevention priorities is guided by the National Commission on Prevention Priorities (NCPP).

    ACIP Recommendation: The ACIP recommendation for persons aged 65 and older was updated in September 2015 to simplify the protocol. Now the ACIP recommends that both PCV13 and PPSV23 be given in series to adults in that age group. A dose of PCV13 should be provided initially and followed with a dose of PPSV23 at least one year later for immunocompetent adults ages 65 or older. The vaccines should not be injected in the same medical visit. If a dose of PPSV23 is inadvertently administered earlier than the recommended interval, the dose need not be repeated. The estimates in this report may not reflect current ACIP recommendations. Readers are advised to check for updated recommendations at

  • publication date
  • 2015
  • Research
  • Economics
  • Models
  • Pneumococcal Vaccines
  • Prevention
  • Risk Factors
  • Screening